In a nutshell This trial is aiming to assess the effectiveness of nivolumab (Opdivo) with or without ipilimumab (Yervoy) in treating metastatic prostate cancer according to the percentage of CD8 cells patients have. The main outcomes that are to be measured are the clinical benefit rate and the percentage of CD8 cells on biopsy during...
Read More
In a nutshell The aim of this study was to evaluate the safety and effectiveness of a cancer vaccine for patients with advanced melanoma. The study found that the vaccine was safe and increased patient survival without worsening of the disease. Some background Treatment for early-stage melanoma includes surgery to remove the tumor. For...
Read More
In a nutshell This trial was carried out to compare osimertinib (Tagrisso) with other EGFR inhibitors to examine its effectiveness in treating advanced non-small cell lung cancer (NSCLC). The authors found that this treatment was effective in increasing survival without cancer worsening in these patients. Some background NSCLC is...
Read More
In a nutshell This study reviewed the current NCCN guidelines for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). Some background Metastatic castration-resistant prostate cancer (mCRPC) is an aggressive form of PC that has spread and is no longer responsive to hormonal therapy such as androgen deprivation...
Read More
In a nutshell This study evaluated the safety and effectiveness of nivolumab (Opdivo) in patients with advanced melanoma in a real-world practice. The study found that the safety and effectiveness of nivolumab in these patients were similar to that reported in clinical trials. Some background Melanoma is a form of skin cancer. In more advanced...
Read More
In a nutshell The aim of this study was to evaluate if cell-free circulating tumor DNA (ctDNA) in the blood could predict a patient's response to targeted therapy. The study found that measuring ctDNA could predict how a patient would respond to therapy. Some background Melanoma is a form of skin cancer. Treatment for early-stage...
Read More
In a nutshell This study investigated the effects of the removal of the breast tumor in patients newly diagnosed with stage IV breast cancer and bone metastasis only. The data showed that removal of the breast tumor improved survival outcomes and decreased the recurrence rates in these patients. Some background In stage IV breast cancer (BC), the...
Read More
In a nutshell The study compared the effectiveness of bicalutamide (Casodex) to enzalutamide (Xtandi), both in combination with androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC). The comparison showed that enzalutamide with ADT improves the outcomes particularly in Black men with mHSPC. Some...
Read More
In a nutshell This study investigated the effectiveness and safety of stereotactic ablative radiation therapy (SABR) in the treatment of patients with oligometastatic (few metastases) cancer. The data showed that the use of SABR in these patients was associated with high overall survival and low toxicity. Some background Oligometastatic cancer (OMC)...
Read More
In a nutshell This study evaluated the impact of radiotherapy (RT) on controlling brain metastasis (BM). The study suggested that a single dose of RT was effective in controlling small BM. Larger BM could be controlled more effectively with multiple rounds of RT. Some background The spread of cancer from the original tumor to other parts of the body...
Read More
In a nutshell This study evaluated the safety and effectiveness of two chemotherapy regimens (SOX and mFOLFOX6) before surgery for rectal cancer (RC) without radiotherapy. The study found that both regimens were safe and effective in these patients. Some background RC is commonly treated with surgery to remove the tumor. Patients with...
Read More
In a nutshell This article looked at the effectiveness and safety of anlotinib (AL3818) for non-responsive advanced non-small cell lung cancer (NSCLC). The authors found that anlotinib was an effective third-line or later line therapy for patients with unresponsive advanced NSCLC. Some background NSCLC accounts for 85% of lung cancers found...
Read More
